Geode Capital Management
TSHA icon

Geode Capital Management’s Taysha Gene Therapies TSHA Stock Holding History

Geode Capital Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.7M Buy
5,531,955
+144,929
+3% +$674K ﹤0.01% 1883
2025
Q4 		$29.6M Buy
5,387,026
+212,510
+4% +$1.03M ﹤0.01% 1793
2025
Q3 		$16.9M Buy
5,174,516
+1,380,944
+36% +$3.91M ﹤0.01% 2085
2025
Q2 		$8.77M Buy
3,793,572
+128,840
+4% +$280K ﹤0.01% 2446
2025
Q1 		$5.1M Buy
3,664,732
+92,383
+3% +$155K ﹤0.01% 2644
2024
Q4 		$6.18M Buy
3,572,349
+9,591
+0.3% +$19.9K ﹤0.01% 2636
2024
Q3 		$7.16M Buy
3,562,758
+682,273
+24% +$1.5M ﹤0.01% 2566
2024
Q2 		$6.45M Buy
2,880,485
+1,860,694
+182% +$5.41M ﹤0.01% 2587
2024
Q1 		$2.93M Buy
1,019,791
+34,370
+3% +$71.6K ﹤0.01% 2958
2023
Q4 		$1.74M Buy
985,421
+523,755
+113% +$1.04M ﹤0.01% 3159
2023
Q3 		$1.46M Buy
461,666
+103,813
+29% +$194K ﹤0.01% 3184
2023
Q2 		$237K Sell
357,853
-18,611
-5% -$13.5K ﹤0.01% 3969
2023
Q1 		$300K Buy
376,464
+44,723
+13% +$57.8K ﹤0.01% 3858
2022
Q4 		$749K Buy
331,741
+91,326
+38% +$185K ﹤0.01% 3494
2022
Q3 		$464K Buy
240,415
+2,176
+0.9% +$7.9K ﹤0.01% 3761
2022
Q2 		$886K Sell
238,239
-171,331
-42% -$680K ﹤0.01% 3484
2022
Q1 		$2.67M Buy
409,570
+18,719
+5% +$140K ﹤0.01% 3106
2021
Q4 		$4.55M Buy
390,851
+27,835
+8% +$420K ﹤0.01% 2941
2021
Q3 		$6.76M Buy
363,016
+99,574
+38% +$1.89M ﹤0.01% 2730
2021
Q2 		$5.58M Buy
263,442
+110,980
+73% +$2.56M ﹤0.01% 2823
2021
Q1 		$3.09M Sell
152,462
-11,352
-7% -$307K ﹤0.01% 3029
2020
Q4 		$4.35M Buy
+163,814
New +$3.53M ﹤0.01% 2675

Other funds holding TSHA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management's TSHA Position: Q1 2026 in Review

Geode Capital Management increased its Taysha Gene Therapies (TSHA) stake by 2.7% in Q1 2026, buying an estimated $674K and bringing the position to 5,531,955 shares worth $24.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1883.

Geode Capital Management first reported a position in TSHA in Q4 2020 and has held it in 22 quarters since. The position peaked at $29.6M in Q4 2025. 191 funds tracked by Wall St. Rank hold TSHA as of Q1 2026.

  • Geode Capital Management held 5,531,955 shares of Taysha Gene Therapies worth $24.7M as of Q1 2026.
  • Geode Capital Management bought 144,929 Taysha Gene Therapies shares in Q1 2026, an estimated $674K.
  • Taysha Gene Therapies made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #1883 holding.
  • Geode Capital Management first reported a position in Taysha Gene Therapies in Q4 2020 and has held it in 22 quarters since.
  • Geode Capital Management's Taysha Gene Therapies position peaked at $29.6M in Q4 2025.
  • 191 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.